TrialBMJ open2018

Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.

Pan-Pan Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.